CGM sensors in India: what they are and who benefits
Medically reviewed by Dr. Om J Lakhani on 18 Oct 2026 · Updated 18 Oct 2026
Short answer
A continuous glucose monitor (CGM) is a small sensor worn on the skin that reads your sugar every few minutes, day and night, and shows trends that finger-prick tests miss. It helps most people who use insulin, especially those with type 1 diabetes or frequent low sugars, and it can also help some people with type 2 diabetes understand how food and activity affect them. In India, sensors are available from pharmacies and online, but each one lasts about two weeks, so the cost adds up and is worth discussing with your doctor.
A finger-prick glucometer gives you a single snapshot. A continuous glucose monitor, or CGM, is more like a video. It shows where your sugar is, which way it is heading, and what happened overnight while you slept. For many people with diabetes, especially those on insulin, this changes how safely and confidently they live day to day.
What is a CGM and how does it work?
A CGM has a small sensor that sits on the back of your upper arm or on your belly. A thin, flexible filament just under the skin measures sugar in the fluid between your cells (interstitial fluid) every few minutes. The readings go to your phone or a reader.
Because it measures this fluid and not blood, a CGM runs a few minutes behind a finger-prick reading. The gap is most noticeable when sugar is changing quickly, for example after a meal or during exercise. This is normal and not a fault. If a reading does not match how you feel, a finger-prick check is the safer guide. Read why glucometer and lab readings differ.
What types are available?
- Real-time CGM sends readings to your phone automatically and can sound alarms for high or low sugar.
- Professional CGM is worn for about two weeks, often placed in the clinic. Your doctor downloads the data afterwards to see your patterns.
- Older “scan to read” sensors needed you to swipe a reader over the sensor. Newer models in India send readings automatically.
Newer guidance, including the American Diabetes Association’s 2026 standards, increasingly groups CGMs as real-time, professional or over-the-counter devices, though the exact terms vary.
What is time in range?
CGM reports introduced a new measure called time in range (TIR), the percentage of the day your sugar stays between 70 and 180 mg/dL. International consensus targets for most adults with diabetes are:
- more than 70% of the time in range
- less than 4% of the time below 70 mg/dL
- less than 1% of the time below 54 mg/dL
Older adults and people at high risk of low sugar have gentler targets, and pregnancy has tighter ones. The report also shows an average picture of a typical day, called the ambulatory glucose profile, which helps you and your doctor spot patterns. The international time-in-range consensus notes that a TIR of about 70% roughly corresponds to an HbA1c of about 7%. Read what your HbA1c result means.
Who benefits most from a CGM?
- People with type 1 diabetes. CGM is now considered a standard part of care, and it lowers HbA1c and low sugars. Read type 1 diabetes in adults.
- Anyone on insulin, including people with type 2 diabetes. The 2026 ADA standards recommend offering CGM to people on insulin from early in treatment. Read starting insulin: what to expect.
- People who get frequent or unnoticed low sugars, including older adults.
- Pregnancy with diabetes, where tight control matters for the baby.
- People using insulin pumps. CGM is needed for automated insulin delivery. Read insulin pumps and automated insulin delivery.
- Some people with type 2 diabetes not on insulin, who use a sensor for a few weeks to learn how their usual Indian meals, such as rice, roti or sweets, and their walking or sleep, affect their sugar.
A CGM is a tool, not a treatment. It helps most when you and your doctor review the data together and act on it.
What is availability and cost like in India?
This section reflects what we could verify as of October 2026. Brands, models and prices change often.
CGM sensors are sold in India through pharmacies, hospitals and online. Abbott’s FreeStyle Libre range is widely used, and in August 2025 Abbott launched the FreeStyle Libre 2 Plus in India, which sends readings to a phone every minute with optional alarms. Several other international and Indian brands are also on the market.
Each sensor usually lasts about 10 to 15 days, so continuous use means buying a new sensor roughly twice a month. For most families this is a recurring cost of several thousand rupees a month, and many insurance policies cover little or none of it. Some people use a sensor continuously, while others use one for a couple of weeks at a time, a few times a year, to guide treatment changes. Ask your doctor which approach gives you the most value. Buy sensors from reliable sources, check the expiry date, and keep them at the temperature the pack advises.
What are the practical downsides?
- mild skin irritation or allergy to the adhesive in some people
- sensors falling off early, especially with sweat or in hot weather
- readings that are less accurate in the first day or at very low or very high sugars
- some medicines, such as high-dose vitamin C, can affect some sensors. Check your sensor’s leaflet.
- “alarm fatigue” if alerts are set too tight
What should I ask my doctor?
- Would a CGM change my treatment or safety?
- Should I use it all the time or for short periods?
- What time-in-range target is right for me?
- How should I share my data before each visit?
To discuss whether a CGM suits you, book a consultation.
When to see an endocrinologist
- Your CGM shows repeated low readings, or you have had a low sugar that needed help from someone else
- Your CGM reading does not match how you feel: check with a finger-prick meter before acting, and seek urgent care if you feel very unwell
- You spend less than half your time in range, or your sugars stay high for long periods
- Redness, swelling, pus or pain at the sensor site that does not settle
Chest pain, fainting, severe breathlessness or confusion: call 108 or 112, or go to the nearest emergency department.
Book In-Person / Online ConsultationWatch the video
References
- American Diabetes Association. 7. Diabetes technology: Standards of Care in Diabetes 2026. Diabetes Care 2026 (PMID 41358889)
- Battelino T et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019 (PMID 31177185)
- Holt RIG et al. The management of type 1 diabetes in adults. The updated 2026 consensus report by the ADA and EASD. Diabetes Care 2026 (PMID 42742157)
- Abbott India. Press release: Abbott launches next-gen FreeStyle Libre 2 Plus with continuous glucose readings every minute and optional alarms. 21 August 2025
This page is general health information and does not replace a consultation with your own doctor. Please read our medical disclaimer.